Hyperhomocysteinemia in myelodysplastic syndromes: Specific association with autoimmunity and cardiovascular disease

A. Cortelezzi, N. S. Fracchiolla, F. Bamonti-Catena, M. Motta, G. Cighetti, M. Carrabba, V. Cavalca, A. T. Maiolo, G. L. Deliliers

Research output: Contribution to journalArticlepeer-review


Hyperhomocysteinemia (HH) has been associated with cardiovascular and autoimmune diseases and oxidative cell damage. Myelodysplastic syndromes (MDS) are associated with autoimmunity (AI) and increased oxidative stress. We tested the association of HH and oxidative stress in 33 MDS patients, by measuring plasma homocysteine and malondialdehyde (MDA). HH was found in 42% of cases, 4/5 cases with associated cardiovascular events (CVE)(80%), and 9/15 cases with associated AI (60%). Thus in MDS, HH was significantly associated with AI/CVE (Χ 2:p=0.0011), and this association seems to be specific, as demonstrated by the comparison of MDS presenting AI/CVE with the ischemic cardiopathy/rheumatoid arthritis control group (13/20, 65% vs 19/69, 27%; Χ 2:p=0.0021). The levels of MDA indicated increased oxidative stress. Our data may suggest that in a subset of MDS, HH may simultaneously contribute to bone marrow myelodysplasia, CVE and AI pathogenesis, possibly through oxidative cell damage.

Original languageEnglish
Pages (from-to)147-150
Number of pages4
JournalLeukemia and Lymphoma
Issue number1-2
Publication statusPublished - 2001


  • Autoimmunity
  • Hyperhomocysteinemia
  • Myelodysplastic syndrome
  • Oxidative stress

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Hyperhomocysteinemia in myelodysplastic syndromes: Specific association with autoimmunity and cardiovascular disease'. Together they form a unique fingerprint.

Cite this